The Margin Came From Spending Less, Not Charging More
Revenue growth of 17% is solid for a pharmaceutical manufacturer, but it is not what produced a 36% rise in profit. Gross margin barely moved: gross profit of ₦24.13 billion on revenue of ₦70.24 billion is 34.4%, against 34.0% a year earlier, with cost of sales up to ₦46.11 billion. The leverage sat below the gross line. Marketing expenses fell by half, to ₦1.30 billion from ₦2.64 billion, and that single line accounts for most of the gap between gross profit growth of 18% and operating profit growth of 34%. Administrative expenses rose to ₦5.78 billion from ₦4.89 billion, partly offsetting the saving, but not enough to change the direction.
The acute segment remains the engine of the top line, contributing ₦40.24 billion of the ₦70.24 billion total. That concentration matters for how the result should be read: the profit improvement came from cost control in a business whose revenue still depends heavily on one product category, rather than from a broad mix shift.
Finance Costs Are the Price of the Expansion
The balance sheet explains the finance cost line. Property, plant and equipment rose to ₦53.07 billion from ₦42.67 billion in September 2025, and total assets grew 19.3% to ₦93.35 billion. MeCure spent ₦16.69 billion on investing activities in the nine months, most of it on plant and equipment, against ₦10.05 billion a year earlier. Liabilities climbed to ₦68.77 billion from ₦60.41 billion, so equity of ₦24.59 billion funds only about a quarter of the asset base. Finance costs of ₦8.84 billion consumed 51% of operating profit, a ratio that leaves the pre-tax line sensitive to borrowing rates even when operations perform.
Cash flow, at least, moved the right way. Operating activities generated ₦10.36 billion, reversing the ₦5.40 billion outflow of the prior period, and cash closed at ₦4.32 billion despite the heavier investment programme. Financing inflows slowed to ₦4.17 billion from ₦17.54 billion, which suggests the current expansion phase is being carried more by operations and existing facilities than by fresh borrowing at last year's pace.
A ₦224.8 Billion Valuation With Little Room for Slippage
MeCure trades at ₦56.20, a market capitalisation of ₦224.8 billion, and the shares are down 13.8% this year despite the earnings growth. At that value the market is paying roughly 28 times annualised nine-month earnings for a company whose profit growth currently rests on a marketing line that has already been cut in half. That line cannot fall at the same rate again. The next phase of growth has to come from the ₦53.07 billion plant base earning its keep, at a finance cost that is rising faster than revenue. The third quarter offered early evidence, with standalone profit up 48% to ₦2.57 billion, but the full test is whether the new capacity lifts revenue growth above 17% before the interest bill narrows the operating gains.
